Hypothesis

Baseline serum indole-3-propionic acid (IPA) concentrations predict the rate of epigenetic aging, as measured by DunedinPACE, independent of chronological age and gut microbiome diversity, through AhR‑PXR‑dependent activation of hepatic SIRT1.

Rationale

• Preclinical work shows IPA extends lifespan in Drosophila and improves musculoskeletal function in aged mice by activating AhR and PXR, stabilizing Wnt/β‑catenin and dampening NF‑κB signaling (PubMed).
• IPA crosses the blood‑brain barrier and correlates with reduced Aβ burden and cognitive improvement in APP/PS1 mice (Science Advances).
• In humans, lower serum IPA associates with post-menopausal osteoporosis, and engineered Clostridium sporogenes restores bone loss in ovariectomized mice (Taylor & Francis).
• Despite these mechanistic insights, IPA has never been evaluated as a longitudinal biomarker of biological age in human cohorts, and no study has linked it to epigenetic clocks such as GrimAge or DunedinPACE.

Novel Mechanism

Beyond AhR/PXR signaling, we propose that hepatic uptake of IPA stimulates SIRT1 deacetylase activity via increased NAD⁺ bioavailability. SIRT1 activation then deacetylates core clock components (e.g., BMAL1) and histone residues, slowing the epigenetic drift captured by DunedinPACE. This links microbial metabolite flux directly to the epigenetic aging machinery.

Testable Predictions

1. In a large, diverse aging cohort (e.g., UK Biobank or the Framingham Heart Study), baseline serum IPA will be negatively associated with change in DunedinPACE over a 5‑year follow‑up after adjusting for age, sex, BMI, diet, and baseline microbiome alpha‑diversity (effect size Cohen’s d ≈ 0.20–0.30).
2. The association will persist when stratifying by AhR loss‑of‑function polymorphisms (e.g., rs2066853) and will be attenuated in carriers of reduced‑function alleles, supporting a causal role of AhR signaling.
3. Mendelian randomization using genetic variants influencing hepatic IPA synthesis or transport (e.g., SNPs in SLC22A7 or CYP2E1) will show a causal effect of higher genetically predicted IPA on slower DunedinPACE progression.
4. In a sub‑study with colonic biopsies, higher IPA levels will correlate with increased intestinal IL‑22 expression and decreased serum IL‑6, linking gut barrier integrity to systemic inflammation and epigenetic aging.

Experimental Design

• Participants: 3,000 adults aged 45‑80, balanced for sex and ethnicity, with baseline serum IPA measured by LC‑MS/MS, gut microbiome shotgun metagenomics, and epigenetic blood DNA methylation (Illumina EPIC array) at visit 1 and visit 2 (5 years later).
• Outcome: Change in DunedinPACE (ΔDunedinPACE) between visits.
• Analysis: Linear mixed models with random intercept for participant, fixed effects for baseline IPA, covariates, and interaction terms with AhR genotype; mediation analysis testing SIRT1 activity (measured in plasma) as intermediary.
• Replication: Repeat analysis in an independent cohort (e.g., ASPREE) and in a centenarian subset to assess whether IPA maintains its predictive value at extreme ages.
• Falsifiability: If baseline IPA shows no significant association with ΔDunedinPACE after full adjustment, or if the association disappears when controlling for IL‑6 or SIRT1 activity, the hypothesis would be refuted.

This framework directly addresses the gap highlighted by the absence of IPA from current biological age panels and offers a concrete, mechanistic pathway that can be validated—or rejected—using existing longitudinal resources.